Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo

International Journal of Molecular Medicine

Volumn 32, Issue 3, 2013, Pages 623-628

  Zhang, Xiaolei ^a   Liu, Peishu ^a   Zhang, Bo ^b   Mao, Hongluan ^a   Shen, Liang ^a   Ma, Yanhui ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Decoy oligodeoxynucleotides; In vivo; Ovarian cancer; Signal transducer and activator of transcription 3

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; GELATINASE A; GELATINASE B; PROTEIN BCL 2; STAT3 DECOY OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGODEOXYRIBONUCLEOTIDES; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880406031     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1431     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward B, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics. CA Cancer J Clin 56: 106-130,2006.
2. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward B, Ries LA, etal: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97: 1407-1427, 2005.
3. Bromberg JF: Activation of STAT proteins and growth control. Bioessays 23: 161-169, 2001.
4. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002.
5. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, FernandezLuna JL, Nunez G, Dalton WS and Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999.
6. Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, Rosen EM and Fan S: Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 488: 179-184, 2001.
7. Al Zaid Siddiquee K and Turkson J: STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18: 254-267, 2008.
8. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY and Hung MC: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7: 575-589, 2005.
9. Park OK, Schaefer TS and Nathans D: In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci USA 93: 13704-13708, 1996.
10. Turkson J and Jove R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19: 6613-6626, 2000.
11. Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2648-2673, 2000.
12. Landen CN Jr, Lin YG, Armaiz Pena GN, et al: Neuroendocrine modulation of signal transducer and activator of transcription 3 in ovarian cancer. Cancer Res 67: 10389-10396, 2007.
13. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV: Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12: 5055-5063, 2006.
14. Nefedova Y and Gabrilovich DI: Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets 7: 7 1-77, 2007.
15. Schlessinger K and Levy DE: Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 65: 5828-5834, 2005.
16. Cai L,Zhang G, Tong X, You Q,An Y, Wang Y, Guo L,Wang T, Zhu D and Zheng J: Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA. Eur J Obstet Gynecol Reprod Biol 148: 73 80, 2010.
17. Yang L, Ma X, Xiao L, Tang M, Weng X, Sun L and Cao Y: Uniquely modified RNA oligonucleotides targeting STAT3 suppress melanoma growth both in vitro and in vivo. Cancer Biol Ther 8: 2065-2072, 2009.
18. Gu J, Li G, Sun T, Su Y, Zhang X, Shen J, Tian Z and Zhang J: Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 89: 9-17. 2008.
19. Souissi I, Najjar I, Ah-Koon L, etal: A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-icB. BMC Cell Biology 12: 14,2011.
20. Zhang X, Liu P, Zhang B, Wang A and Yang M: Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet 197: 46-53, 2010.
21. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF and Grandis JR: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 100: 4138-4143,2003.
22. Zhang X, Zhang L, Wang L, Wei H and Tian Z: Therapeutic effects of STAT3-decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 7: 149, 2007.
23. Devalapally H, Duan Z, Seiden MV and Amiji MM: Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res 14: 3193-3203, 2008.
24. Mao HL, Liu PS, Zheng JF, Zhang PH, Zhou LG, Xin G and Liu C: Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro. Pharmacol Res 56: 4 83-492, 2007.
25. Bromberg J: Stat proteins and oncogenesis: J Clin Invest 109: 1139-1142, 2002.
26. Fletcher S, Turkson J and Gunning PT: Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 3: 1159-1168,2008.
27. Leeman RJ, Lui VW and Grandis JR: STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6: 231-241, 2006.
28. Colomiere M, Findlay J, Ackland L and Ahmed N: Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6betal integrin. Int J Biochem Cell Biol 41: 1034-1045,2009.
29. Jing N and Tweardy DJ: Targeting Stat3 in cancer therapy. Anticancer Drugs 16: 601-607, 2005.
30. Shen J, Li Rand Li G: Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. In Vivo 23: 237-243, 2009.
31. Liotta LA and Stetler-Stevenson WG : Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51 (Suppl 18): 5054S-5059S, 1991.
32. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G and Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63: 5224-5229, 2003.
33. dos Santos LG, Lopes-Costa PV, dos Santos AR, Facina G and da Silva BB: Bcl-2 oncogene expression in estrogen receptor- positive and negative breast carcinoma. Eur J Gynaecol Oncol 29: 459-461,2008.
34. Alas Sand Bonavida B: Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 9: 316-326, 2003.
35. Selvendiran K, Koga H, Ueno T, et al: Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res 66: 4826-4834, 2006.
36. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A and Nagata S: A caspase-activated DNase that degrades DNA during apoptosis and its inhibitor ICAD. Nature 391: 43-50, 1998.
37. Kamada S, Kikkawa U, Tsujimoto Y and Hunter T: Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s). J Biol Chem 280: 857-860, 2005.